Skip to content

Study · Systematic review · n = 34,721 · 2024

5 results

Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.

Masson W, Lobo M, Barbagelata L, Lavalle-Cobo A, Nogueira JP

Endocrinologia, diabetes y nutricion1 Mar 2024Cited by 17 (Europe PMC)

PMID38555109 (opens in a new tab)DOI10.1016/j.endien.2024.03.012 (opens in a new tab)PepBankPUB-38555109
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis of placebo-controlled trials, semaglutide was not associated with an increased risk of acute pancreatitis overall.

    In plain wordsIn pooled trials, semaglutide was not linked to a higher risk of acute pancreatitis than placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute pancreatitis risk, all regimens
    Study

    n = 34,721

    Comparator
    Placebo
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    0.7 ratio
    all semaglutide regimens

    Source sentences

    Summary
    Globally, semaglutide therapy was not associated with an increased risk of acute pancreatitis (OR 0.7; 95% CI 0.5-1.2, I2 0%).
    1 context sentence
    Summary · context
    We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis, oral semaglutide was not associated with an increased risk of acute pancreatitis versus placebo.

    In plain wordsIn pooled trials, oral semaglutide was not linked to a higher risk of acute pancreatitis than placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute pancreatitis risk, oral semaglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    OR
    0.4 ratio
    oral semaglutide

    Source sentences

    Summary
    group with oral semaglutide: OR 0.40; 95% CI 0.10-1.60
    1 context sentence
    Summary · context
    We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis.
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis, low-dose subcutaneous semaglutide was not associated with an increased risk of acute pancreatitis versus placebo.

    In plain wordsIn pooled trials, low-dose injected semaglutide was not linked to a higher risk of acute pancreatitis than placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute pancreatitis risk, low subcutaneous doses
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    low doses · subcutaneousAs given in this study (human).

    Measurements

    OR
    0.8 ratio
    low subcutaneous doses

    Source sentences

    Summary
    group with low subcutaneous doses of semaglutide: OR 0.80; 95% CI 0.40-1.90
    1 context sentence
    Summary · context
    We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis.
  4. 04HumanSystematic reviewSafety outcome

    In a meta-analysis, high-dose subcutaneous semaglutide was not associated with an increased risk of acute pancreatitis versus placebo.

    In plain wordsIn pooled trials, high-dose injected semaglutide was not linked to a higher risk of acute pancreatitis than placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute pancreatitis risk, high subcutaneous doses
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    high doses · subcutaneousAs given in this study (human).

    Measurements

    OR
    0.7 ratio
    high subcutaneous doses

    Source sentences

    Summary
    group with high subcutaneous doses of semaglutide: OR 0.70; 95% CI 0.50-1.20
    1 context sentence
    Summary · context
    We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis.
  5. 05HumanSystematic reviewSafety outcome

    In a meta-analysis, acute pancreatitis risk with semaglutide did not differ significantly between the oral, low-dose and high-dose subcutaneous regimens.

    In plain wordsIn pooled trials, the pancreatitis risk with semaglutide did not differ significantly between oral, low-dose and high-dose injected regimens.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute pancreatitis risk, difference between regimens
    Study

    n: not reported in source

    Comparator
    Other semaglutide regimens
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    interaction p-value=0.689).
    1 context sentence
    Summary · context
    We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.